

Accelerating Cell Line Development with SynWeave™

Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous cell lines.

Combined with advanced clone screening using the Ambr® 250 platform, SynWeave™ helps identify high-performing clones faster, reducing development timelines while maintaining critical quality attributes and scalability.




SynWeave™: Setting a New Standard in Cell Line Development

- 01 Higher Integration Efficiency**
 Utilizes transposon-mediated integration to enable reliable and efficient gene insertion, overcoming the limitations of low integration rates.
- 02 Reduced Heterogeneity**
 Minimizes variability associated with random gene integration, producing more uniform clones with reduced position-effect variation.
- 03 Accelerated Development Timeline**
 Shortens cell line development timelines by enabling faster progression from transfection to clone selection.
- 04 Enhanced Product Quality**
 Selects high-yield clones with consistent product quality through rigorous assessment of titer and critical quality attributes.
- 05 Reliable Outcomes**
 Delivers reproducible performance and consistent results, reducing development risk and minimizing the need for rework.

Demonstrated 9 g/L IgG Titters (mAb)



High-Performing Clones in Just 9 Weeks from Transfection



For more information, contact bdc@syngeneintl.com
www.syngeneintl.com